(Q34103173)

31 July 2017

1 reference

title

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists (English)

1 reference

31 July 2017

0 references

0 references

0 references

Patrik Roser

1

1 reference

PubMed ID

20218784

31 July 2017

Franz X Vollenweider

series ordinal

2

1 reference

PubMed ID

20218784

31 July 2017

Wolfram Kawohl

series ordinal

3

1 reference

31 July 2017

1 March 2010

1 reference

World Journal of Biological Psychiatry

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

2 Pt 2

1 reference

31 July 2017

208-219

1 reference

Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function.

31 July 2017

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Schizophrenia: a subcortical neurotransmitter imbalance syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Atypicality of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

21 January 2018

Safety of obesity drugs

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabis use and psychotic disorders: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabinoid receptor localization in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Psychiatric effects of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Diagnosing schizophrenia in the initial prodromal phase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Dopamine, the prefrontal cortex and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Influence of postweaning social isolation in the rat on brain development, conditioned behavior, and neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Different effects of nabilone and cannabidiol on binocular depth inversion in Man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabis-associated psychosis: current status of research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

To model a psychiatric disorder in animals: schizophrenia as a reality test

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The endogenous cannabinoid receptor agonist anandamide impairs memory in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabis and acute psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

A Total Synthesis of dl-Δ1-Tetrahydrocannabinol, the Active Constituent of Hashish1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabidiol: an overview of some pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The Mechanism of Action of Novel Antipsychotic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Reversible effects of acute and long-term administration of delta-9-tetrahydrocannabinol (THC) on memory in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabinoid-induced Fos expression within A10 dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The acute effects of cannabinoids on memory in humans: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabinoid function in learning, memory and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Role of the endogenous cannabinoid system in the regulation of motor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Agonistic properties of cannabidiol at 5-HT1a receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The orphan receptor GPR55 is a novel cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Pharmacological and molecular targets in the search for novel antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Reduced binocular depth inversion in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Impact of substance abuse on the course and outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Mismatch negativity in schizophrenia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

A systems model of altered consciousness: integrating natural and drug-induced psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Cannabidiol monotherapy for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

Marijuana use in schizophrenia: a clear hazard

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970801908047

10.3109/15622970801908047

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

20218784